Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 10Condylomata Acuminata 10Papillomavirus Infections 5Vulvar Neoplasms 3Vaginal Neoplasms 3Uterine Cervical Dysplasia 1Penile Neoplasms 1Neoplasms 1Cancer Survivor 1Anus Neoplasms 1

Interventions

Fluorouracil 26Radiotherapy 17Mitomycin 17Cisplatin 12Capecitabine 12pembrolizumab 10Cyclophosphamide 9Radiation 8Paclitaxel 8fludarabine 7Specimen Handling 7Nivolumab 7Carboplatin 7Magnetic Resonance Spectroscopy 6Cetuximab 6Biopsy 6Papillomavirus Vaccines 5Drug Therapy 5dehydroftorafur 4aldesleukin 4Vaccines 4Radiotherapy, Intensity-Modulated 4Irinotecan 4Watchful Waiting 3Taxes 3Oxaliplatin 3Observation 3Light Coagulation 3Ipilimumab 3Interleukin-2 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Anus Neoplasms × Vaccines, Synthetic × Clear all
NCT06465914 2024-12-12

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males

Shanghai Bovax Biotechnology Co., Ltd.

Phase 3 Active not recruiting
9,000 enrolled
GastrointestinalGenitourinary

Anus Neoplasms, Condylomata Acuminata, Penile Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡